# Safety, Pharmacokinetics, and Pharmacodynamic Testing of Rabies mAb CBB 1

> **NCT05832073** · EARLY_PHASE1 · UNKNOWN · sponsor: **Changchun BCHT Biotechnology Co.** · enrollment: 152 (estimated)

## Conditions studied

- Rabies Virus Infection

## Interventions

- **DRUG:** Natural full human monoclonal antibody CBB 1 injection
- **DRUG:** Rabies Human Immunoglobulin (HRIG)
- **DRUG:** Natural full human monoclonal antibody CBB 1 injection placebo
- **BIOLOGICAL:** Lyophilized rabies vaccine for human use (Vero cells)

## Key facts

- **NCT ID:** NCT05832073
- **Lead sponsor:** Changchun BCHT Biotechnology Co.
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-04-30
- **Primary completion:** 2023-12-30
- **Final completion:** 2024-04-30
- **Target enrollment:** 152 (ESTIMATED)
- **Last updated:** 2023-04-27

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05832073

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05832073, "Safety, Pharmacokinetics, and Pharmacodynamic Testing of Rabies mAb CBB 1". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT05832073. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*